Approach to Drug-Induced Hepatitis

Initial Management

The American Association for the Study of Liver Diseases recommends immediate discontinuation of all potentially hepatotoxic medications upon suspicion of drug-induced hepatitis, as this is the only proven effective intervention for most cases 1, 2
A detailed medication history, including all prescription drugs, over-the-counter medications, herbal supplements, and dietary products taken over the past year, should be obtained, with specific attention to timing, dosage, and last dose 2
The latency period from drug exposure to symptom onset, typically 1-8 weeks to 3-12 months, should be determined, as minocycline and nitrofurantoin can exceed 12 months 1
Features of hypersensitivity, such as fever, rash, or eosinophilia, suggesting idiosyncratic reaction, should be assessed 1

Hepatic transaminases (ALT, AST), total and direct bilirubin, alkaline phosphatase, and INR should be obtained to characterize the pattern and severity of injury 1, 2
Competing etiologies, including viral hepatitis serologies (HAV, HBV, HCV), autoimmune markers (ANA, ASMA, anti-LKM1), and imaging to rule out biliary obstruction, should be excluded 1, 2

Drug-induced autoimmune-like hepatitis can be indistinguishable from classical autoimmune hepatitis, but several features assist differentiation, including acute onset, absence of cirrhosis at presentation, and complete resolution after drug withdrawal 3, 4, 5
The European Association for the Study of the Liver recommends considering ursodeoxycholic acid (UDCA) 13-15 mg/kg/day for cholestatic drug-induced liver injury 3, 2, 6

Glucocorticoid therapy should be instituted in cases meeting Hy's law criteria (ALT >3× ULN AND total bilirubin >2× ULN), which increases the risk of death or need for liver transplantation in 9-12% of patients 1, 7
The American Association for the Study of Liver Diseases recommends glucocorticoid therapy in cases of failure of laboratory tests to improve after discontinuation of the medication, worsening of symptoms or laboratory tests, and severe symptomatic disease with significant clinical deterioration 1, 7, 2

Resolution typically occurs within 1 month (rarely 3 months) after drug discontinuation, and monitoring should continue until complete and sustained resolution of clinical and laboratory findings 1, 7
Repeat liver function tests within 7-10 days after drug discontinuation, and continue monitoring until alkaline phosphatase normalizes or returns to baseline, total bilirubin normalizes, and clinical symptoms resolve 2, 6

Patients with pre-existing liver disease, chronic alcohol users, and patients with cirrhosis and decompensation require special consideration and coordination with a transplant center 2
Minocycline and nitrofurantoin account for 90% of drug-induced autoimmune-like hepatitis cases, and drugs implicated in 9% of patients with clinical phenotype of autoimmune hepatitis should be avoided 3, 4, 5, 8, 9

Individuals who consume alcohol heavily have a markedly higher risk of developing drug‑induced liver injury, even when alcohol consumption is stopped during therapy. 10
These patients should undergo more frequent clinical assessments and laboratory monitoring of liver enzymes and bilirubin. 10

Isoniazid is generally regarded as safe for use during pregnancy, but the likelihood of hepatitis is increased during the peripartum period. 10
When isoniazid is prescribed to pregnant patients, supplementation with pyridoxine (approximately 25 mg daily) is advised to mitigate neurotoxicity risk. 10

Isoniazid can be administered to patients with severe renal dysfunction, including those on chronic hemodialysis, without requiring dose adjustment. 10
In the presence of underlying liver disease, the potential for drug accumulation and consequent drug‑induced hepatitis is heightened, necessitating more intensive laboratory and clinical surveillance. 10